OTCMKTS:IGXT IntelGenx Technologies Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.15 0.00 (0.00 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$0.15Now: $0.15▼$0.1650-Day Range$0.15MA: $0.17▼$0.2152-Week Range$0.12Now: $0.15▼$0.70Volume7,845 shsAverage Volume461,948 shsMarket Capitalization$16.54 millionP/E RatioN/ADividend YieldN/ABeta2.04 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestSocial Media IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingIntelGenx Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.85, IntelGenx Technologies has a forecasted upside of 466.7% from its current price of $0.15.Amount of Analyst CoverageIntelGenx Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesIntelGenx Technologies has received 171 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntelGenx Technologies has received 176 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntelGenx Technologies has received 50.72% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote “Outperform” if you believe IGXT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IGXT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntelGenx Technologies does not currently pay a dividend.Dividend GrowthIntelGenx Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IntelGenx Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.19% of the stock of IntelGenx Technologies is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IntelGenx Technologies are expected to grow in the coming year, from ($0.06) to ($0.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IntelGenx Technologies is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IntelGenx Technologies is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IGXT Previous Symbol CUSIP45822R101 CIK1098880 Webwww.intelgenx.com Phone514-331-7440Debt Debt-to-Equity Ratio4.20 Current Ratio1.08 Quick Ratio0.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$740,000.00 Price / Sales22.35 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.11) Net Income$-10,660,000.00 Net Margins-2,567.02% Return on Equity-540.96% Return on Assets-79.19%Miscellaneous Employees38 Outstanding Shares110,260,000Market Cap$16.54 million Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $0.15 0.00 (0.00 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IGXT News and Ratings via Email Sign-up to receive the latest news and ratings for IGXT and its competitors with MarketBeat's FREE daily newsletter. IntelGenx Technologies (OTCMKTS:IGXT) Frequently Asked Questions How has IntelGenx Technologies' stock been impacted by COVID-19 (Coronavirus)? IntelGenx Technologies' stock was trading at $0.3950 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IGXT shares have decreased by 62.0% and is now trading at $0.15. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of IntelGenx Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IntelGenx Technologies. When is IntelGenx Technologies' next earnings date? IntelGenx Technologies is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for IntelGenx Technologies. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) released its earnings results on Thursday, August, 13th. The company reported ($0.16) earnings per share for the quarter. The firm earned $0.04 million during the quarter. IntelGenx Technologies had a negative net margin of 2,567.02% and a negative return on equity of 540.96%. View IntelGenx Technologies' earnings history. What price target have analysts set for IGXT? 2 Wall Street analysts have issued 12 month price objectives for IntelGenx Technologies' stock. Their forecasts range from $0.50 to $1.20. On average, they expect IntelGenx Technologies' stock price to reach $0.85 in the next year. This suggests a possible upside of 466.7% from the stock's current price. View analysts' price targets for IntelGenx Technologies. Are investors shorting IntelGenx Technologies? IntelGenx Technologies saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 64,600 shares, a drop of 38.5% from the August 15th total of 105,100 shares. Based on an average daily trading volume, of 357,700 shares, the short-interest ratio is presently 0.2 days. View IntelGenx Technologies' Short Interest. Who are some of IntelGenx Technologies' key competitors? Some companies that are related to IntelGenx Technologies include Infinity Pharmaceuticals (INFI), Eyenovia (EYEN), Savara (SVRA), Aridis Pharmaceuticals (ARDS), Anixa Biosciences (ANIX), Proteostasis Therapeutics (PTI), Aerpio Pharmaceuticals (ARPO), Aerpio Pharmaceuticals (ARPO), Citius Pharmaceuticals (CTXR), Soligenix (SNGX), Onconova Therapeutics (ONTX), Adamis Pharmaceuticals (ADMP), Processa Pharmaceuticals (PCSA), Monopar Therapeutics (MNPR) and Cocrystal Pharma (COCP). View all competitors. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), KemPharm (KMPH), New Residential Investment (NRZ), SemiLEDs (LEDS), BIOLASE (BIOL), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI) and Corbus Pharmaceuticals (CRBP). Who are IntelGenx Technologies' key executives? IntelGenx Technologies' management team includes the following people: Dr. Horst G. Zerbe, Founder, Chairman, CEO, Pres & Chairman of Scientific Advisory Board (Age 72)Mr. Andre Godin C.A., CPA, CPA, CA, Exec. VP & CFO (Age 55)Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 41)Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 42)Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 65) What is IntelGenx Technologies' stock symbol? IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT." How do I buy shares of IntelGenx Technologies? Shares of IGXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is IntelGenx Technologies' stock price today? One share of IGXT stock can currently be purchased for approximately $0.15. How big of a company is IntelGenx Technologies? IntelGenx Technologies has a market capitalization of $16.54 million and generates $740,000.00 in revenue each year. The company earns $-10,660,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. IntelGenx Technologies employs 38 workers across the globe. What is IntelGenx Technologies' official website? The official website for IntelGenx Technologies is www.intelgenx.com. How can I contact IntelGenx Technologies? IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The company can be reached via phone at 514-331-7440 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
